European Heart Journal Advance Access first published online on March 17, 2005
This version published online on March 21, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi190
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine, Research Center, Montreal Heart Institute, 5000 Belanger Street E,H1T 1C8 Montreal, Canada
* To whom correspondence should be addressed. Aims Heart rate reduction is the cornerstone of the treatment of angina. The purpose of this study was to explore the prognostic value of heart rate in patients with stable coronary artery disease (CAD). Methods and results We assessed the relationship between resting heart rate at baseline and cardiovascular mortality/morbidity, while adjusting for risk factors. A total of 24 913 patients with suspected or proven CAD from the Coronary Artery Surgery Study registry were studied for a median follow-up of 14.7 years. All-cause and cardiovascular mortality and cardiovascular rehospitalizations were increased with increasing heart rate (P<0.0001). Patients with resting heart rate Conclusion Resting heart rate is a simple measurement with prognostic implications. High resting heart rate is a predictor for total and cardiovascular mortality independent of other risk factors in patients with CAD.
Received October 22, 2004
Revised February 1, 2005
Accepted February 3, 2005
Clinical research
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease
2 Montreal Heart Institute Coordinating Center (MHICC), Montreal, Quebec, Canada
Jean-Claude Tardif, E-mail: jean-claude.tardif{at}icm-mhi.org
Abstract 
83 bpm at baseline had a significantly higher risk for total mortality [hazard ratio (HR)=1.32, CI 1.19-1.47, P<0.0001] and cardiovascular mortality (HR=1.31, CI 1.15-1.48, P<0.0001) after adjustment for multiple clinical variables when compared with the reference group. When comparing patients with heart rates between 77-82 and 83 bpm with patients with a heart rate 
62 bpm, the HR values for time to first cardiovascular rehospitalization were 1.11 and 1.14, respectively (P<0.001 for both).
The originally published version of this paper was incorrect. The first author's name was incorrectly spelt and should have appeared as 'Ariel Diaz'. The author apologizes that this error was not identified earlier.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Swedberg, M. Komajda, M. Bohm, J. S. Borer, I. Ford, and L. Tavazzi Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) Eur J Heart Fail, November 5, 2009; (2009) hfp154v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fox, I. Ford, Ph. G. Steg, M. Tendera, M. Robertson, R. Ferrari, and on behalf of the BEAUTIFUL Investigators Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial Eur. Heart J., October 1, 2009; 30(19): 2337 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Thorin and N. Thorin-Trescases Vascular endothelial ageing, heartbeat after heartbeat Cardiovasc Res, October 1, 2009; 84(1): 24 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bangalore, F. H. Messerli, F.-S. Ou, J. Tamis-Holland, A. Palazzo, M. T. Roe, M. K. Hong, E. D. Peterson, and for the CRUSADE Investigators The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative Eur. Heart J., September 30, 2009; (2009) ehp397v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif Heart rate and atherosclerosis Eur. Heart J. Suppl., August 1, 2009; 11(suppl_D): D8 - D12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease) Eur. Heart J. Suppl., August 1, 2009; 11(suppl_D): D19 - D27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Steg Heart rate management in coronary artery disease: the CLARIFY registry Eur. Heart J. Suppl., August 1, 2009; 11(suppl_D): D13 - D18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Christensen, R.-l. Zhang, W. Zheng, J. J. Campanelli, E. I. Dedkov, R. M. Weiss, and R. J. Tomanek Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H322 - H330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif Heart rate as a treatable cardiovascular risk factor Br. Med. Bull., June 1, 2009; 90(1): 71 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mukaddam-Daher, A. Menaouar, P.-A. Paquette, M. Jankowski, J. Gutkowska, M.-A. Gillis, Y.-F. Shi, A. Calderone, and J.-C. Tardif Hemodynamic and Cardiac Effects of Chronic Eprosartan and Moxonidine Therapy in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, May 1, 2009; 53(5): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sajadieh A new combination therapy in stable angina pectoris Eur. Heart J., March 1, 2009; 30(5): 524 - 525. [Full Text] [PDF]
|
|
|
|
|
|
A. Tverdal, V. Hjellvik, and R. Selmer Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379 843 men and women aged 40-45 years Eur. Heart J., November 2, 2008; 29(22): 2772 - 2781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Ivabradine for stable angina? DTB, November 1, 2008; 46(11): 84 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bangalore, S. Sawhney, and F. H. Messerli Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Borer Heart rate: from risk marker to risk factor Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F2 - F6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari, C. Ceconi, and G. Guardigli Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F7 - F10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif The pivotal role of heart rate in clinical practice: from atherosclerosis to acute coronary syndrome Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F11 - F16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Custodis, M. Baumhakel, N. Schlimmer, F. List, C. Gensch, M. Bohm, and U. Laufs Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, May 6, 2008; 117(18): 2377 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kolloch, U. F. Legler, A. Champion, R. M. Cooper-DeHoff, E. Handberg, Q. Zhou, and C. J. Pepine Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST) Eur. Heart J., May 2, 2008; 29(10): 1327 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Palatini Is there benefit of cardiac slowing drugs in the treatment of hypertensive patients with elevated heart rate? Eur. Heart J., May 2, 2008; 29(10): 1218 - 1220. [Full Text] [PDF]
|
|
|
|
 |
|
 A S Hall and S Palmer The heart rate hypothesis: ready to be tested Heart, May 1, 2008; 94(5): 561 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]
|
|
|
|
|
|
A. Hjalmarson Heart rate: an independent risk factor in cardiovascular disease Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F3 - F7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Steg Overview of large morbidity/mortality trials with ivabradine: focus on the BEAUTIfUL study Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F15 - F19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fox, J. S. Borer, A. J. Camm, N. Danchin, R. Ferrari, J. L. Lopez Sendon, P. G. Steg, J.-C. Tardif, L. Tavazzi, M. Tendera, et al. Resting Heart Rate in Cardiovascular Disease J. Am. Coll. Cardiol., August 28, 2007; 50(9): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Rogowski, I Shapira, A Shirom, S Melamed, S Toker, and S Berliner Heart rate and microinflammation in men: a relevant atherothrombotic link Heart, August 1, 2007; 93(8): 940 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. York, M. Hassan, Q. Li, H. Li, R. B. Fillingim, and D. S. Sheps Coronary Artery Disease and Depression: Patients With More Depressive Symptoms Have Lower Cardiovascular Reactivity During Laboratory-Induced Mental Stress Psychosom Med, July 1, 2007; 69(6): 521 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Donnelly and G. Manning Review: Angiotensin-converting enzyme inhibitors and coronary heart disease prevention Journal of Renin-Angiotensin-Aldosterone System, March 1, 2007; 8(1): 13 - 22. [Abstract] [PDF]
|
|
|
|
|
|
S. Cook, M. Togni, M. C. Schaub, P. Wenaweser, and O. M. Hess High heart rate: a cardiovascular risk factor? Eur. Heart J., October 2, 2006; 27(20): 2387 - 2393. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif and C. Berry From coronary artery disease to heart failure: potential benefits of ivabradine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D24 - D29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif, A. Diaz, and M. G. Bourassa Heart rate reduction through lifestyle modification: reply Eur. Heart J., September 1, 2005; 26(17): 1807 - 1807. [Full Text] [PDF]
|
|
|
|
|
|
A. Michalsen and G. J. Dobos Heart rate reduction through lifestyle modification Eur. Heart J., September 1, 2005; 26(17): 1806 - 1807. [Full Text] [PDF]
|
|
|
|
|
|
M. Tendera Editorial: If inhibition: from pure heart reduction to treatment of stable angina Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H3 - H6. [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H16 - H21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif Ivabradine in clinical practice: benefits of If inhibition Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H29 - H32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Palatini Heart rate: a strong predictor of mortality in subjects with coronary artery disease Eur. Heart J., May 2, 2005; 26(10): 943 - 945. [Full Text] [PDF]
|
|